Sanofi’s Viehbacher enthusiastic about new biotech pacts; Argos yanks IPO; Telaprevir effective in HIV patients

@FierceBiotech: Protein-based nanofiber envisioned for use in delivering cardio, Alzheimer's drugs. Story | Follow @FierceBiotech

@JohnCFierce: Mersana does an ADC development deal with Endo--$270M in biobucks. Release | Follow @JohnCFierce

@RyanMFierce: Not surprised. Accelrys (software for drug discovery labs) barely topped analyst EPS estimates for 4Q '11. More | Follow @RyanMFierce

> Continuing to speak out on one of his favorite themes, Sanofi ($SNY) CEO Chris Viehbacher told a conference in Boston that he's particularly enthusiastic about striking up new collaborations with biotech companies as a way to drive innovation at the pharma giant. After scaling down internal R&D, Sanofi has been looking externally for new and better therapies in the biotech pipeline. Story

> GE Healthcare has acquired Xcellerex, a biopharmaceutical manufacturer with expertise in recombinant proteins, antibodies and vaccines. No financial terms were disclosed. Release

> New data demonstrates that two new hepatitis C drugs from Vertex Pharmaceuticals ($VTRX) and Merck ($MRK) are effective in patients who are also infected with HIV. The Vertex drug, telaprevir, proved superior. Story

> Argos Therapeutics has yanked its IPO, citing market conditions. MedCity News reports that Argos will have to find some other way to fund Phase III cancer studies. Report

> As part of the buyout deal with Amgen ($AMGN), Micromet CEO Christian Itin and the rest of the executive team have resigned and been replaced by Amgen execs. Story

Pharma News

@FiercePharma: GSK's 19%-owned Aspen Pharmacare grew first-half sales 31% as Asia-Pacific revenues triple--Reuters. Article | Follow @FiercePharma

> Pradaxa patient's death draws more scrutiny of bleeding risks. Story

> Whistleblower claims Takeda blunted Actos heart reports. News

Medical Device News

> Abbott, Merck keep companion Dx trend going with cancer test. Article

> Accelmed, Peregrine Ventures pump up NLT Spine's funding to $14.5M. News

> FDA warns Synthes facility over complaint handling procedures. More

> Roche tries to pressure Illumina to start talking. Item

Biomarkers News

> Biomarkers warn of kidney injury after heart surgery. Story

> Biomarkers expose child cancer treatment heart risk. Article

> Mitochondria changes could track Alzheimer's disease. More

> Urine test could point out colon cancers. Item

Drug Delivery News

> Conceal drug delivery tech to avoid immune system wrath. Story

> With J&J deal undone, Orexo revamps drug delivery tech development. More

> Tekmira seeks court's rejection of Alnylam drug delivery patent suit. Article

> Protein-based nanofiber envisioned for drug delivery use. Item

And Finally… Boston-based Akili Interactive, which is being incubated at PureTech, is developing new therapeutic video games. Report

Suggested Articles

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost.

Sumitomo is looking to the merged pipeline to help offset the anticipated impact of the arrival of generic competitors to bipolar drug Latuda.